UNSPSC 51142031: Pidolacetamol

This classification denotes an analgesic and antipyretic with the molecular formula C13H14N2O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 693SRA99OH, chemically known as 5-oxo-l-proline, ester with 4-hydroxyacetanilide but generally known as pidolacetamol, which bears US NIH Compound Identifier 65920. European Medicines Agency schedules Pidolacetamol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09824MIG.

UNSPSC 51142031 Pidolacetamol is a Commodity code that nominally covers a single pharmaceutical active ingredient, but recent state and local solicitations tagged under this code are actually procuring naloxone, generic multi-source pharmaceuticals, and over-the-counter products through pharmacy benefit and direct-to-manufacturer programs. State and local governments buying under this code include county health departments, state health and human services agencies, and regional cooperative purchasing alliances that supply multiple participating jurisdictions. The scope reflects a mix of emergency medical supplies (naloxone and drug deactivation systems for community health initiatives), generic pharmaceutical inventory management through established wholesaler networks, and exploratory procurement to establish direct manufacturer relationships outside traditional pharmacy benefit manager and group purchasing organization channels. Issuing bodies range from individual counties to state departments to multistate cooperative purchasing vehicles, with the latter serving the broadest geographic footprint across multiple states and participating municipalities.

Activity centers in Florida and Texas with multistate reach through cooperative purchasing. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 drug deactivation systems annually with quarterly deliveries, response due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription fulfillment outside traditional PBM and GPO arrangements, with no binding procurement timeline attached. The Minnesota Department of Administration's Office of State Procurement, on behalf of the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed through AmerisourceBergen, Cardinal Health, and Morris & Dickson, response due March 26, 2026, with contracts effective July 1, 2026. The mismatch between the code's nominal scope (pidolacetamol, a specific acetaminophen metabolite) and the actual procurements (broad pharmaceutical categories, naloxone, OTC products) suggests that tagging inconsistency has placed diverse pharmacy-related solicitations under this narrow code.